GW Pharmaceuticals plc Revenue and Competitors

GW Pharmaceuticals is a cutting-edge UK-based biopharmaceutical company that over the last 20 years has established a world-leading position in cannabinoid science and the development of regulatory approved medicines derived from cannabis. Our mission is to transform the lives of seriously ill patients and their families. In October 2018 our achievements were recognized by TIME magazine which named GW as one of the Top 50 Genius companies of 2018 that are inventing the future. Having developed the world's first prescription medicine derived from the cannabis plant, Sativex®, which treats spasticity due to multiple sclerosis GW has now developed an oral formulation of purified cannabidiol (CBD), (approved as Epidiolex® in the U.S) for seizures associated with Lennox-Gastaut syndrome or Dravet Syndrome, two rare and severe early-onset, drug-resistant epilepsy syndromes. This is in addition to our deep pipeline of clinical stage cannabinoid product candidates under development for both orphan and non-orphan indications with a particular focus on neurological conditions. In the UK we have close to 550 employees from a diverse range of backgrounds and disciplines based on four sites in Cambridge, Kent, London and Andover, along with employees working in the field. We also have a strong presence in the U.S. with around 250 U.S. employees, based both in Carlsbad, CA and in the field. We are continuing to build out our teams and are looking for talented individuals dedicated to making a difference in the lives of our patients, and to exemplifying our company values.